{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:02:35Z","timestamp":1778889755772,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T00:00:00Z","timestamp":1614729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Soldatentumorhilfe"},{"DOI":"10.13039\/501100004168","name":"Universit\u00e4t zu L\u00fcbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004168","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Plasmablastic lymphoma (PBL) is a rare and aggressive B-cell malignancy with a heterogenous clinical and prognostic spectrum, determined by multiple factors, including age, HIV- and <jats:italic>MYC<\/jats:italic>-status. While there exist several validated scoring systems for diffuse large B-cell lymphoma, which incorporate basic clinical features (age, lactate dehydrogenase, sites of (extranodal) involvement, stage and performance), none of these have been systematically assessed in PBL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We determined the (age-adjusted; aa)-International Prognostic Index (IPI), revised IPI (R-IPI), and National Comprehensive Cancer Network IPI (NCCN-IPI) in a comprehensive multi-center cohort (<jats:italic>n<\/jats:italic>\u2009=\u200978) of PBL patients. Further, all indices were comparatively investigated for model quality and concordance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Univariate analysis revealed significant prognostic capabilities for all indices, all of which identified a subgroup with favorable outcome. Discriminatory power between patients with less benign prognosis and especially refractory disease exhibited significant variability. Subsequently, stratified models for each risk score were compared employing corrected Akaike\u2019s information criterion (cAIC) and Harrel\u2019s concordance index (c-index). Here, the NCCN-IPI outperformed both IPI and R-IPI regarding c-index with ambiguous cAIC results, underlining its clinical utility and suggesting it for preferential use in clinical practice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our current observations support the use of the IPI and its enhanced derivatives in PBL patients. There is, however, a distinct requirement for novel prognostic tools to better delineate subgroups at risk for early relapse or refractory disease as well as late relapse. A comprehensive molecular characterization of a clinically annotated cohort of PBL patients is therefore urgently warranted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-021-03580-z","type":"journal-article","created":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T18:20:09Z","timestamp":1614795609000},"page":"3043-3050","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Performance of international prognostic indices in plasmablastic lymphoma: a comparative evaluation"],"prefix":"10.1007","volume":"147","author":[{"given":"Nadine","family":"Hertel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Merz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz-Wolfram","family":"Bernd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Axel","family":"K\u00fcnstner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hauke","family":"Busch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas","family":"von Bubnoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred C.","family":"Feller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-7125","authenticated-orcid":false,"given":"Hanno M.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,3]]},"reference":[{"key":"3580_CR1","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automatic Control AC 19:716\u2013723","journal-title":"IEEE Trans Automatic Control AC"},{"key":"3580_CR2","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3324\/haematol.2014.111112","volume":"99","author":"SK Barta","year":"2014","unstructured":"Barta SK et al (2014) A new prognostic score for AIDS-related lymphomas in the rituximab-era. Haematologica 99:1731\u20131737. https:\/\/doi.org\/10.3324\/haematol.2014.111112","journal-title":"Haematologica"},{"key":"3580_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B et al (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679\u2013690. https:\/\/doi.org\/10.1038\/s41591-018-0016-8","journal-title":"Nat Med"},{"key":"3580_CR4","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ et al (1997) Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89:1413\u20131420","journal-title":"Blood"},{"key":"3580_CR5","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/ajh.24169","volume":"90","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC et al (2015) Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol 90:1041\u20131046. https:\/\/doi.org\/10.1002\/ajh.24169","journal-title":"Am J Hematol"},{"key":"3580_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3109\/10428194.2014.907896","volume":"56","author":"N Gebauer","year":"2015","unstructured":"Gebauer N, Bernard V, Gebauer W, Thorns C, Feller AC, Merz H (2015) TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. Leuk Lymphoma 56:179\u2013185. https:\/\/doi.org\/10.3109\/10428194.2014.907896","journal-title":"Leuk Lymphoma"},{"key":"3580_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s10985-015-9330-3","volume":"22","author":"G Heller","year":"2016","unstructured":"Heller G, Mo Q (2016) Estimating the concordance probability in a survival analysis with a discrete number of risk groups. Lifetime Data Anal 22:263\u2013279. https:\/\/doi.org\/10.1007\/s10985-015-9330-3","journal-title":"Lifetime Data Anal"},{"key":"3580_CR8","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors P","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"3580_CR9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-015-0163-z","volume":"8","author":"S Loghavi","year":"2015","unstructured":"Loghavi S et al (2015) Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol 8:65. https:\/\/doi.org\/10.1186\/s13045-015-0163-z","journal-title":"J Hematol Oncol"},{"key":"3580_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/his.13959","volume":"76","author":"L Miao","year":"2020","unstructured":"Miao L, Guo N, Feng Y, Rao H, Wang F, Huang Q, Huang Y (2020) High incidence of MYC rearrangement in human immunodeficiency virus-positive plasmablastic lymphoma. Histopathology 76:201\u2013211. https:\/\/doi.org\/10.1111\/his.13959","journal-title":"Histopathology"},{"key":"3580_CR11","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bjh.14489","volume":"176","author":"C Montalban","year":"2017","unstructured":"Montalban C et al (2017) Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2 -microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol 176:918\u2013928. https:\/\/doi.org\/10.1111\/bjh.14489","journal-title":"Br J Haematol"},{"key":"3580_CR12","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"AS Ruppert","year":"2020","unstructured":"Ruppert AS et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI R-IPI, and NCCN-IPI. Blood 135:2041\u20132048. https:\/\/doi.org\/10.1182\/blood.2019002729","journal-title":"Blood"},{"key":"3580_CR13","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R et al (2018) Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 378:1396\u20131407. https:\/\/doi.org\/10.1056\/NEJMoa1801445","journal-title":"N Engl J Med"},{"key":"3580_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1097\/QAD.0b013e32835e069d","volume":"27","author":"P Schommers","year":"2013","unstructured":"Schommers P et al (2013) Poor outcome of HIV-infected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS 27:842\u2013845. https:\/\/doi.org\/10.1097\/QAD.0b013e32835e069d","journal-title":"AIDS"},{"key":"3580_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH et al (2007) The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857\u20131861. https:\/\/doi.org\/10.1182\/blood-2006-08-038257","journal-title":"Blood"},{"key":"3580_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/03610927808827599","volume":"7","author":"N Sugiura","year":"1978","unstructured":"Sugiura N (1978) Further analysts of the data by akaike\u2019 s information criterion and the finite corrections. Commun Stat Theory Methods 7:13\u201326. https:\/\/doi.org\/10.1080\/03610927808827599","journal-title":"Commun Stat Theory Methods"},{"key":"3580_CR17","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"3580_CR18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mdw684","volume":"28","author":"E Tchernonog","year":"2017","unstructured":"Tchernonog E et al (2017) Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol 28:843\u2013848. https:\/\/doi.org\/10.1093\/annonc\/mdw684","journal-title":"Ann Oncol"},{"key":"3580_CR19","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/modpathol.3800355","volume":"18","author":"F Vega","year":"2005","unstructured":"Vega F et al (2005) Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol 18:806\u2013815. https:\/\/doi.org\/10.1038\/modpathol.3800355","journal-title":"Mod Pathol"},{"key":"3580_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41408-020-0327-0","volume":"10","author":"HM Witte","year":"2020","unstructured":"Witte HM et al (2020) Clinicopathological characteristics and MYC status determine treatment outcome in plasmablastic lymphoma: a multi-center study of 76 consecutive patients. Blood Cancer J 10:63. https:\/\/doi.org\/10.1038\/s41408-020-0327-0","journal-title":"Blood Cancer J"},{"key":"3580_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z et al (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123:837\u2013842. https:\/\/doi.org\/10.1182\/blood-2013-09-524108","journal-title":"Blood"},{"key":"3580_CR22","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","volume":"28","author":"M Ziepert","year":"2010","unstructured":"Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, Loeffler M (2010) Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 28:2373\u20132380. https:\/\/doi.org\/10.1200\/JCO.2009.26.2493","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03580-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-021-03580-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-021-03580-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T15:10:29Z","timestamp":1630077029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-021-03580-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,3]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3580"],"URL":"https:\/\/doi.org\/10.1007\/s00432-021-03580-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,3]]},"assertion":[{"value":"28 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}